Literature DB >> 15359110

Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

B Hügle1, P Suchowerskyj, H Hellebrand, B Adler, M Borte, U Sack, U Schulte Overberg-Schmidt, N Strnad, J Otto, A Meindl, V Schuster.   

Abstract

Hypogammaglobulinemia is a common symptom in different immunodeficiencies. It is, however, not usually associated with Epstein-Barr virus (EBV) infections. The X-linked lymphoproliferative disease (XLP) on the other hand shows immunological changes in response to the EBV. Here we report three previously healthy boys, all of which developed persistent hypogammaglobulinemia following severe acute infectious mononucleosis. All three patients revealed T-cell abnormalities including inverted CD4/CD8 and increased CD8(+) T-cell numbers. The number of IFN-gamma-producing T cells were markedly increased in the two patients studied so far. In addition, patient 2 showed mainly T cells, instead of B cells, to be infected with the EBV. Apart from an uncle of patient 3, who died of malignant lymphoma, family history was unremarkable in all cases. All three patients exhibited mutations in the SH2D1A gene, establishing the diagnosis of XLP. Protein expression was found on immunoblot analysis in one patient with a missense mutation. Development of persistent hypogammaglobulinemia after severe primary EBV infection seems to be a specific diagnostic sign for XLP even in males with unremarkable family history.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15359110     DOI: 10.1023/B:JOCI.0000040922.26286.36

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  38 in total

1.  Manifestations of X-linked lymphoproliferative disease without prior Epstein-Barr exposure.

Authors:  V Schuster; K Steppberger; M Borte
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

2.  Monoclonal proliferation of T cells containing Epstein-Barr virus in fatal mononucleosis.

Authors:  M Mori; H Kurozumi; K Akagi; Y Tanaka; S Imai; T Osato
Journal:  N Engl J Med       Date:  1992-07-02       Impact factor: 91.245

3.  SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.

Authors:  L Yin; V Ferrand; M F Lavoué; D Hayoz; N Philippe; G Souillet; M Seri; R Giacchino; E Castagnola; S Hodgson; B S Sylla; G Romeo
Journal:  Hum Genet       Date:  1999-11       Impact factor: 4.132

4.  Common variable immunodeficiency following Epstein-Barr virus infection.

Authors:  G Zuccaro; S Della Bella; B Polizzi; M Vanoli; R Scorza
Journal:  J Clin Lab Immunol       Date:  1997

5.  Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection.

Authors:  S Ohga; A Nomura; H Takada; K Ihara; K Kawakami; F Yanai; Y Takahata; T Tanaka; N Kasuga; T Hara
Journal:  J Infect Dis       Date:  2000-11-21       Impact factor: 5.226

6.  Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients.

Authors:  M Morra; M Simarro-Grande; M Martin; A S Chen; A Lanyi; O Silander; S Calpe; J Davis; T Pawson; M J Eck; J Sumegi; P Engel; S C Li; C Terhorst
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

7.  Immunoregulatory T cells in males vulnerable to Epstein-Barr virus with the X-linked lymphoproliferative syndrome.

Authors:  P K Lai; N Yasuda; D T Purtilo
Journal:  Am J Pediatr Hematol Oncol       Date:  1987

8.  Immune-deficient bronchiectasis associated with X-linked lymphoproliferative disease.

Authors:  V K Mehta; M G Massad; S P Tripathi; M Koshy; A S Geha
Journal:  Ann Thorac Surg       Date:  1999-08       Impact factor: 4.330

9.  Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma.

Authors:  O Parolini; B Kagerbauer; I Simonitsch-Klupp; P Ambros; U Jaeger; G Mann; O A Haas; M Morra; H Gadner; C Terhorst; W Knapp; W Holter
Journal:  Ann Hematol       Date:  2002-07-20       Impact factor: 3.673

10.  X-linked lymphoproliferative disease. Detection of a paternally inherited mutation in a German family using haplotype analysis.

Authors:  V Schuster; W Kress; W Friedrich; T Grimm; H W Kreth
Journal:  Am J Dis Child       Date:  1993-12
View more
  3 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  X-linked lymphoproliferative disease in an adult.

Authors:  Takumi Hoshino; Hirokazu Kanegane; Noriko Doki; Hiroyuki Irisawa; Tohru Sakura; Yoshihisa Nojima; Shuichi Miyawaki; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

3.  X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.

Authors:  Tao Xu; Qin Zhao; Wenyan Li; Xuemei Chen; Xiuhong Xue; Zhi Chen; Xiao Du; Xiaoming Bai; Qian Zhao; Lina Zhou; Xuemei Tang; Xi Yang; Hirokazu Kanegane; Xiaodong Zhao
Journal:  Eur J Pediatr       Date:  2019-11-21       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.